Seibersdorf Labor GmbH and Isotopia Molecular Imaging are pleased to announce that they have entered into an agreement for the production of no-carrier-added Lutetium-177, a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer. The production facility is expected to be ready by Q4 2022.
177Lu n.c.a is used in Targeted Radionuclide Therapy in the field of Precision Oncology. By binding n.c.a. Lu-177 isotopes to tumor-specific targeting molecules, the resulting radiopharmaceutical targets the tumor and delivers precise cell-killing radiation that spares normal healthy tissue. Isotopia has developed a reliable and unique GMP method to produce a highly pure form of Lu-177. 177Lu n.c.a contains no Mercury (Hg) and no metastable Lu-177m, therefore there is no need for cost intensive clinical waste management.
Isotopia's CEO & Co-Founder Dr. Eli Shalom stated: This step supports Isotopia’s global strategy to simplify and shorten the supply route to our customers. We have found in Seibersdorf the best partner sharing the same vision to save lives".
Seibersdorf's CEO, Martina Schwaiger stated: “The new production agreement is an exciting opportunity for our organization and we are pleased to be working with Isotopia Molecular Imaging on this important sector of medical care.”
About Isotopia
Isotopia Molecular Imaging Ltd. is a collaboration between The Metrontario Group and Israel’s leading scientists in the field of radiopharmaceuticals. The Isotopia development team is a multidisciplinary team consisting of nuclear pharmacists, radiochemists, nuclear engineers and physicists.
The experienced Isotopia team, together with its nuclear pharmacy, cyclotron facility, Lu-177 production site and sterile manufacturing plant, are a well-established platform for development. Isotopia creates collaborations between the scientific and medical community to further develop and experiment with new markers for imaging applications and molecular therapy. For more information about Isotopia, please visit: www.isotopia.co.il